Kymera Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Co. is developing KT-474, an active and selective, orally bioavailable IRAK4 degrader, for the treatment of IL-1R/TLR-driven immunology-inflammation conditions and diseases. Co. is developing another group of IRAK4 degraders, which Co. calls IRAKIMiDs for the treatment of MYD88-mutated diffuse large B-cell lymphoma. Co. is developing its selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases. The KYMR stock yearly return is shown above.
The yearly return on the KYMR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KYMR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|